| In Silico Re‐Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure–Response Simulation CJ Peer, KT Schmidt, O Arisa, WJ Richardson, K Paydary, DA Goldstein, ... The Journal of Clinical Pharmacology 63 (6), 672-680, 2023 | 4 | 2023 |
| Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs BR Wei, CJ Peer, WJ Richardson, SM Hewitt, WD Figg, RM Simpson Frontiers in Veterinary Science 9, 1056408, 2022 | 3 | 2022 |
| Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer. ND Shore, JW Avitia, JL Bailen, LT Nordquist, W Richardson, CJ Peer, ... Journal of Clinical Oncology 41 (16_suppl), TPS5117-TPS5117, 2023 | | 2023 |
| Determination of metarrestin (ML-246) in human plasma for a first-in-human clinical pharmacokinetic application by a simple and efficient uHPLC-MS/MS assay WJ Richardson, SM Zimmerman, A Reno, NC Cabanas, O Arisa, ... Journal of Chromatography B 1224, 123738, 2023 | | 2023 |
| Phase 1/2a Study of PRL-02, a Long-Acting Intramuscular (IM) Depot Injection of Abiraterone Decanoate in Patients (pts) with Advanced Prostate Cancer J Avitia, R Tutrone, N Shore, J Bailen, L Nordquist, W Richardson, C Peer, ... Journal of Clinical Oncology 41 (6_suppl), 141-141, 2023 | | 2023 |
| Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application JC Goodell, SM Zimmerman, CJ Peer, V Prabhu, T Yin, WJ Richardson, ... Journal of pharmaceutical and biomedical analysis 213, 114685, 2022 | | 2022 |
